Home > Healthcare > Pharmaceuticals > Finished Drug Form > fibrate drugs market
Get a free sample of Fibrate Drugs Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Fibrate Drugs Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The fibrate drugs industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced devices based on different technologies is among a key market strategy. Some of the leading industry players have a notable presence in the market.
Some of the eminent market participants operating in the fibrate drugs industry include:
Clofibrate segment generated a decent revenue in 2023 and is estimated to account for USD 2.1 billion by 2032 as they help in the management of lipid disorders and reducing the risk of cardiovascular events.
North America market was worth USD 1.2 billion in 2023 and is predicted to witness substantial growth through 2032, driven by a robust investment in drug R&D, catering to the needs of elderly population.
Aurobindo Pharma Limited, Abbott Laboratories, Cipla Inc., IOL Chemicals and Pharmaceuticals Limited, Lupin Limited, Mylan N.V., Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd. are some of the major industry contenders.
The global market for fibrate drugs was valued at around USD 3.1 billion in 2023 and is estimated to reach over USD 4.8 billion by 2032, driven by the increasing prevalence of cardiovascular disease.